marked.bio

Company

Shanghai Institute Of Biological Products

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

3 of 4 trials shown

  1. A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients

    Recruiting Phase 1 Shanghai Institute Of Biological Products Started 2025Primary completion 2028-05 NCT06985368

    SIBP-A18

    Queue 1: CLDN18.2 positive late stage gastric cancer/gastroesophageal junction cancer (GC/GEJC) confirmed b…

    Claudin 18.2 expressionSolid Tumor Malignancy

  2. A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

    Recruiting Phase 1 Shanghai Institute Of Biological Products Started 2024Primary completion 2026-04 NCT06298058

    SIBP-A13 formulation for injection

    …cell lung cancer (NSCLC) confirmed by histology or cytology, with disease progression and EGFR mutation during or after treatment with third generation TKI and platinum containing therapy.

    EGFR exon 19 deletion / L858RAdvanced Solid Tumor

  3. A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.

    Recruiting Phase 1 Shanghai Institute Of Biological Products Started 2024Primary completion 2026-07 NCT06512116

    SIBP-A17

    Cohort 1: Late/unresectable and/or metastatic breast cancer with low HER2 expression (IHC1+or IHC2+/FISH -) after standard treatment failure or intolerance.

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Advanced Solid Tumor